Redwire Corporation vs Viatris Inc — how do they compare? Redwire Corporation trades at $8.97 (market cap $2.25B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 9.1× Redwire Corporation's market cap, and Viatris Inc pays a 2.73% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| RDW | VTRS | |
|---|---|---|
Market Cap | $2.25B | $20.50B |
Sector | Technology | Health |
52-Week High | $25.90 | $17.59 |
52-Week Low | $5.06 | $8.74 |
Enterprise Value | $2.31B | $32.71B |
Dividend Yield | — | 2.73% |
Signals from Pluang's Aura AI — not financial advice
Redwire (RDW) trades at $8.60, down 1.78% with a bearish technical signal despite oversold RSI readings. The company shows strong revenue growth potential with a record $492 million backlog and a 1.92 book-to-bill ratio, but faces significant profitability challenges with a net income margin of -80.9% and consecutive earnings misses. Recent expansions in Indiana and Alabama highlight operational growth amid substantial cash burn from operations.
The stock presents a high-risk, high-reward opportunity with an 80% analyst buy rating and a $19.00 consensus price target implying over 120% upside. However, persistent losses, negative cash flow from operations, and potential dilution from a $500 million ATM offering pose substantial risks to near-term shareholder value.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →